IP Verse

Dosage Regimen For A S1P Receptor Agonist

Patent No. EP3453387 (titled "Dosage Regimen For A S1P Receptor Agonist") was filed by Novartis on Dec 21, 2009. The application was issued on Jun 3, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
HAMM & WITTKOPPMar 3, 2021HAMM & WITTKOPP
LABORATORIOS LICONSAMar 3, 2021DR SCHON
VON SEEBACHMar 3, 2021HAMM & WITTKOPP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3453387

NOVARTIS
Application Number
EP18201062A
Filing Date
Dec 21, 2009
Status
Granted And Under Opposition
May 1, 2020
Publication Date
Jun 3, 2020
External Links
Slate, Register , Google Patents